Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FX7X1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $8,339
Award facts
- Contract value 100% obligated
- $8,339.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on August 18, 2025, for the supply of Xtandi 80 mg tablets in quantities of 60. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of August 19, 2025. This award was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete on an unrestricted basis despite its small business status. The delivery location is specified as Park Ridge, Illinois, where the vendor maintains its primary operations.
This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999 and valid through November 2026, which authorizes the agency to issue firm fixed-price orders for a comprehensive range of pharmaceutical products supporting military health facilities worldwide. The Xtandi supply represents a specialized oncology pharmaceutical product, consistent with the vendor's established portfolio of branded prescription medications and biologics supplied to Department of Defense healthcare sites. DMS Pharmaceutical Group has positioned itself as a critical supplier within the federal pharmaceutical supply chain through its long-standing relationship with the DLA and its ability to deliver specialized medical products across multiple therapeutic categories to military treatment facilities.
Quick answers
Who was awarded contract SPE2DB25FX7X1?
SPE2DB25FX7X1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 18, 2025.
How much is contract SPE2DB25FX7X1 worth?
The government has obligated $8,339 on SPE2DB25FX7X1.
Is contract SPE2DB25FX7X1 an order under another contract?
Yes. SPE2DB25FX7X1 is a delivery order under SPE2DB20D9354, an indefinite delivery contract.
Was contract SPE2DB25FX7X1 competed?
The extent of competition for SPE2DB25FX7X1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award